N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-
c]pyridine- 5-carboxamide
hydrochloride PHA 543613
hydrochloride manufacturers
- PHA 543613
-
-
2026-07-10
- CAS:478149-53-0
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20Tons
- PHA 543613
-
- $46.00
-
2026-05-25
- CAS:478149-53-0
- Purity: 99.96%
- Supply Ability: 10g
|
| | N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-
c]pyridine- 5-carboxamide
hydrochloride PHA 543613
hydrochloride Basic information |
| | N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-
c]pyridine- 5-carboxamide
hydrochloride PHA 543613
hydrochloride Chemical Properties |
| Melting point | 313-315 °C | | Boiling point | 508.0±40.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | DMSO: ≥20mg/mL | | form | White powder | | pka | 12.19±0.20(Predicted) | | color | white to off-white | | InChI | 1S/C15H17N3O2/c19-15(12-7-11-3-6-20-14(11)8-16-12)17-13-9-18-4-1-10(13)2-5-18/h3,6-8,10,13H,1-2,4-5,9H2,(H,17,19)/t13-/m0/s1 | | InChIKey | IPKZCLGGYKRDES-ZDUSSCGKSA-N | | SMILES | O=C(N[C@H]1CN2CC[C@H]1CC2)c3cc4ccoc4cn3 |
| WGK Germany | 1 | | Storage Class | 11 - Combustible Solids |
| | N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-
c]pyridine- 5-carboxamide
hydrochloride PHA 543613
hydrochloride Usage And Synthesis |
| Uses | PHA-543613 has been used to study its effect on recognition memory and neurovascular coupling (NVC) response in β-amyloid (Aβ) 25-35-treated mice. It has also been used to study its effect on Aβ25-35-induced receptor alteration and cognitive impairment in mice. | | Definition | ChEBI: Pha-543613 is a phosphoramide and an organothiophosphorus compound. | | Biological Activity | Primary Target α7 nAChR | | in vivo | PHA-543613 (0.3 mg/kg) successfully reverses Scopolamine-induced short-term memory deficits in rats[2].
PHA-543613 (4 and 12 mg/kg; i.p. once) reduces behavioral deficits and brain edema[3]. | Animal Model: | Male CD-1 mice with (intracerebral hemorrhage) ICH-induction or sham surgery[3] | | Dosage: | 4 and 12 mg/kg | | Administration: | Intraperitoneal injection; 4 and 12 mg/kg; 1 hour after surgery | | Result: | Increased p-Akt and decreased p-GSK-3 and CC3 expressions in the ipsilateral hemisphere and reduced the neuronal cell death in the perihematomal area. Attenuated behavioral deficits and
brain edema at 72 hours after ICH.
|
|
| | N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-furo[2,3-
c]pyridine- 5-carboxamide
hydrochloride PHA 543613
hydrochloride Preparation Products And Raw materials |
|